US Stocks
/
Inhibikase Therapeutics, Inc. Share Price

Inhibikase Therapeutics, Inc. Share Price

NASDAQ: IKT | Micro Cap
$1.97
+$0.06 (2.88%) Last updated on 10 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Inhibikase Therapeutics, Inc. Stock Performance

Open
$1.91
Prev. Close
$1.91
Circuit Range
N/A
Day Range
$1.88 - $1.98
Year Range
$1.33 - $2.61
Volume
51,307
Average Traded
$1.93

Inhibikase Therapeutics, Inc. Share Price Today

As of 11 October 2026, Inhibikase Therapeutics, Inc.'s share price is $1.97. The stock opened at $1.91, compared to its previous close of $1.91. During today's trading session, Inhibikase Therapeutics, Inc.'s share price traded between $1.88 and $1.98, with an average price of $1.93. Over the past 52 weeks, the stock has recorded a high of $2.61 and a low of $1.33. In terms of performance, Inhibikase Therapeutics, Inc.'s share price has risen by 3.97% over the last six months and is up 32.77% on a year-on-year basis.

Inhibikase Therapeutics, Inc. Share Price Chart

$1.88$1.98
L
Show Current Price
H

Inhibikase Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$193.18M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.43
Revenue (TTM)
$0.00
Return On Equity (TTM)
-39.55%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-64.21%

Inhibikase Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$11.93-$12.73-$16.38-$19.59
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-6.71%-28.67%-19.60%

Inhibikase Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.12$0.26$0.00$0.00
Net Profit-$18.05-$19.03-$27.52-$48.26
Net Profit Margin-15041.67%-7319.23%N/AN/A
Income ChangeN/A-5.43%-44.61%-75.36%

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Inhibikase Therapeutics, Inc. Historical Returns

MonthOpenCloseChange %
Oct 2026
$2.05
$1.97
-4.61%
Sep 2026
$2.35
$2.06
-16.94%
Aug 2026
$2.23
$2.48
+13.76%
Jul 2026
$2.04
$2.18
+7.44%
Jun 2026
$1.77
$2.03
+16.61%
May 2026
$1.87
$1.74
-7.94%
Apr 2026
$1.71
$1.89
+13.17%
Mar 2026
$1.94
$1.67
-18.54%
Feb 2026
$1.57
$2.05
+36.67%
Jan 2026
$2.04
$1.50
-27.18%
Dec 2025
$1.53
$2.06
+33.33%
Nov 2025
$1.34
$1.54
+4.39%

IKT Share Price FAQs

What is Inhibikase Therapeutics, Inc. share price today?

chevron-up
Inhibikase Therapeutics, Inc. share price today is $1.97 as on October 10, 2026 at 1:29 am IST.

What is the 52 week high and 52 week low of Inhibikase Therapeutics, Inc. stock?

chevron-up
The 52 week high of Inhibikase Therapeutics, Inc. stock is $2.61, while the 52 week low is $1.33 as of 10 Oct '26.

What is IKT's market capitalisation today?

chevron-up
IKT market capitalisation is $193.18M as of October 11, 2026, at 2:06 am IST.

What is IKT's net income for the last quarter?

chevron-up
IKT's net income for the last quarter is -19.59B USD.

What is the 5 year returns of IKT?

chevron-up
The 5 year returns of IKT is -83.54% as on 10 Oct '26.

What is the high & low stock price of IKT today?

chevron-up
IKT stock price hit a high of $1.98 and low of $1.88 as of 10 Oct '26.

Can I buy IKT shares in India?

chevron-up
Yes. You can buy IKT in India by opening an international trading account.